17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Karkoulis, Panagiotis K ^a   Stravopodis, Dimitrios J ^b   Margaritis, Lukas H ^b   Voutsinas, Gerassimos E ^a  

^a INSTITUTE OF NANOSCIENCE AND NANOTECHNOLOGY   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

HEAT SHOCK PROTEIN 90; I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C RECEPTOR; TANESPIMYCIN; TRANSCRIPTION FACTOR FKHR; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; BENZOQUINONE DERIVATIVE; MACROCYCLIC LACTAM; MESSENGER RNA;

APOPTOSIS; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL MOTILITY; CELL SPECIFICITY; CELL SURVIVAL; CELL TYPE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME INACTIVATION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; PROTEIN CLEAVAGE; PROTEIN FUNCTION; PROTEIN SYNTHESIS REGULATION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BLADDER TUMOR; CELL ADHESION; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; DRUG ANTAGONISM; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WOUND HEALING;

APOPTOSIS; BENZOQUINONES; BLOTTING, WESTERN; CELL ADHESION; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; WOUND HEALING;

EID: 77956476510     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-481     Document Type: Article

References (43)

1. Clark PE. Bladder cancer. Curr Opin Oncol 2007, 19(3):241-247. 10.1097/CCO.0b013e3280ad43ac, 17414643.
2. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005, 5(9):713-725. 10.1038/nrc1697, 16110317.
3. Pashos CL, Botteman MF, Laskin BL, Redaelli A. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract 2002, 10(6):311-322. 10.1046/j.1523-5394.2002.106011.x, 12406054.
4. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009, 374(9685):239-249. 10.1016/S0140-6736(09)60491-8, 19520422.
5. Mitra AP, Datar RH, Cote RJ. Molecular staging of bladder cancer. BJU Int 2005, 96(1):7-12. 10.1111/j.1464-410X.2005.05557.x, 15963111.
6. Stravopodis DJ, Margaritis LH, Voutsinas GE. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex. Curr Med Chem 2007, 14(29):3122-3138. 10.2174/092986707782793925, 18220746.
7. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005, 5(10):761-772. 10.1038/nrc1716, 16175177.
8. Picard D. Heat-shock protein 90, a chaperone for folding and regulation. Cell Mol Life Sci 2002, 59(10):1640-1648. 10.1007/PL00012491, 12475174.
9. Pearl LH, Prodromou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 2006, 75:271-294. 10.1146/annurev.biochem.75.103004.142738, 16756493.
10. Maloney A, Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin Biol Ther 2002, 2(1):3-24. 10.1517/14712598.2.1.3, 11772336.
11. Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol 2003, 15(6):419-424. 10.1097/00001622-200311000-00003, 14624223.
12. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006, 13(Suppl 1):S125-135. 10.1677/erc.1.01324, 17259553.
13. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007, 1113:202-216. 10.1196/annals.1391.012, 17513464.
14. Stravopodis DJ, Karkoulis PK, Konstantakou EG, Melachroinou S, Lampidonis AD, Anastasiou D, Kachrilas S, Messini-Nikolaki N, Papassideri IS, Aravantinos G, et al. Grade-dependent effects on cell cycle progression and apoptosis in response to doxorubicin in human bladder cancer cell lines. Int J Oncol 2009, 34(1):137-160.
15. Konstantakou EG, Voutsinas GE, Karkoulis PK, Aravantinos G, Margaritis LH, Stravopodis DJ. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. Int J Oncol 2009, 35(2):401-416.
16. Morales JL, Perdew GH. Carboxyl terminus of hsc70-interacting protein (CHIP) can remodel mature aryl hydrocarbon receptor (AhR) complexes and mediate ubiquitination of both the AhR and the 90 kDa heat-shock protein (hsp90) in vitro. Biochemistry 2007, 46(2):610-621. 10.1021/bi062165b, 2527729, 17209571.
17. Jiang J, Ballinger CA, Wu Y, Dai Q, Cyr DM, Hohfeld J, Patterson C. CHIP is a U-box-dependent E3 ubiquitin ligase: identification of Hsc70 as a target for ubiquitylation. J Biol Chem 2001, 276(46):42938-42944. 10.1074/jbc.M101968200, 11557750.
18. Kundrat L, Regan L. Identification of residues on Hsp70 and Hsp90 ubiquitinated by the cochaperone CHIP. J Mol Biol 395(3):587-594. 10.1016/j.jmb.2009.11.017, 19913553.
19. Giustiniani J, Daire V, Cantaloube I, Durand G, Pous C, Perdiz D, Baillet A. Tubulin acetylation favors Hsp90 recruitment to microtubules and stimulates the signaling function of the Hsp90 clients Akt/PKB and p53. Cell Signal 2009, 21(4):529-539. 10.1016/j.cellsig.2008.12.004, 19136058.
20. Okamoto J, Mikami I, Tominaga Y, Kuchenbecker KM, Lin YC, Bravo DT, Clement G, Yagui-Beltran A, Ray MR, Koizumi K, et al. Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. J Thorac Oncol 2008, 3(10):1089-1095. 10.1097/JTO.0b013e3181839693, 2656438, 18827603.
21. Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 2002, 21(8):1159-1166. 10.1038/sj.onc.1205184, 11850835.
22. Burrows F, Zhang H, Kamal A. Hsp90 activation and cell cycle regulation. Cell Cycle 2004, 3(12):1530-1536.
23. Garcia-Morales P, Carrasco-Garcia E, Ruiz-Rico P, Martinez-Mira R, Menendez-Gutierrez MP, Ferragut JA, Saceda M, Martinez-Lacaci I. Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G(2)/M arrest in glioblastoma cell lines. Oncogene 2007, 26(51):7185-7193. 10.1038/sj.onc.1210534, 17525741.
24. Hostein I, Robertson D, DiStefano F, Workman P, Clarke PA. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res 2001, 61(10):4003-4009.
25. Mediavilla-Varela M, Pacheco FJ, Almaguel F, Perez J, Sahakian E, Daniels TR, Leoh LS, Padilla A, Wall NR, Lilly MB, et al. Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Mol Cancer 2009, 8(1):68. 10.1186/1476-4598-8-68, 2741463, 19715609.
26. Byun JY, Kim MJ, Yoon CH, Cha H, Yoon G, Lee SJ. Oncogenic Ras signals through activation of both phosphoinositide 3-kinase and Rac1 to induce c-Jun NH2-terminal kinase-mediated, caspase-independent cell death. Mol Cancer Res 2009, 7(9):1534-1542. 10.1158/1541-7786.MCR-08-0542, 19723872.
27. Cardillo MR, Sale P, Di Silverio F. Heat shock protein-90, IL-6 and IL-10 in bladder cancer. Anticancer Res 2000, 20(6B):4579-4583.
28. Lebret T, Watson RW, Molinie V, O'Neill A, Gabriel C, Fitzpatrick JM, Botto H. Heat shock proteins HSP27, HSP60, HSP70, and HSP90: expression in bladder carcinoma. Cancer 2003, 98(5):970-977. 10.1002/cncr.11594, 12942564.
29. Lebret T, Watson RW, Molinie V, Poulain JE, O'Neill A, Fitzpatrick JM, Botto H. HSP90 expression: a new predictive factor for BCG response in stage Ta-T1 grade 3 bladder tumours. Eur Urol 2007, 51(1):161-166. discussion 166-167, 10.1016/j.eururo.2006.06.006, 16828965.
30. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425(6956):407-410. 10.1038/nature01913, 14508491.
31. Clarke PA, Hostein I, Banerji U, Stefano FD, Maloney A, Walton M, Judson I, Workman P. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 2000, 19(36):4125-4133. 10.1038/sj.onc.1203753, 10962573.
32. McCollum AK, Teneyck CJ, Sauer BM, Toft DO, Erlichman C. Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. Cancer Res 2006, 66(22):10967-10975. 10.1158/0008-5472.CAN-06-1629, 17108135.
33. Beck R, Verrax J, Gonze T, Zappone M, Pedrosa RC, Taper H, Feron O, Calderon PB. Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death. Biochem Pharmacol 2009, 77(3):375-383. 10.1016/j.bcp.2008.10.019, 19014912.
34. Shen SC, Yang LY, Lin HY, Wu CY, Su TH, Chen YC. Reactive oxygen species-dependent HSP90 protein cleavage participates in arsenical As(+3)- and MMA(+3)-induced apoptosis through inhibition of telomerase activity via JNK activation. Toxicol Appl Pharmacol 2008, 229(2):239-251. 10.1016/j.taap.2008.01.018, 18336854.
35. Brader S, Eccles SA. Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori 2004, 90(1):2-8.
36. Gazitt Y, Kolaparthi V, Moncada K, Thomas C, Freeman J. Targeted therapy of human osteosarcoma with 17AAG or rapamycin: characterization of induced apoptosis and inhibition of mTOR and Akt/MAPK/Wnt pathways. Int J Oncol 2009, 34(2):551-561.
37. Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH, Dietmaier W, Bolder U, Schlitt HJ, Geissler EK, et al. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther 2007, 6(3):1123-1132. 10.1158/1535-7163.MCT-06-0628, 17363505.
38. Hovelmann S, Beckers TL, Schmidt M. Molecular alterations in apoptotic pathways after PKB/Akt-mediated chemoresistance in NCI H460 cells. Br J Cancer 2004, 90(12):2370-2377. 2409515, 15150572.
39. Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 2006, 12(2):584-590. 10.1158/1078-0432.CCR-05-1194, 16428504.
40. Jia W, Yu C, Rahmani M, Krystal G, Sausville EA, Dent P, Grant S. Synergistic antileukemic interactions between 17-AAG and UCN-01 involve interruption of RAF/MEK- and AKT-related pathways. Blood 2003, 102(5):1824-1832. 10.1182/blood-2002-12-3785, 12738674.
41. Xie Q, Gao CF, Shinomiya N, Sausville E, Hay R, Gustafson M, Shen Y, Wenkert D, Vande Woude GF. Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion. Oncogene 2005, 24(23):3697-3707. 10.1038/sj.onc.1208499, 15782129.
42. Wang S, Pashtan I, Tsutsumi S, Xu W, Neckers L. Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors. Cell Cycle 2009, 8(13):2050-2056.
43. Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006, 12(12):3657-3660. 10.1158/1078-0432.CCR-06-0818, 16778093.